In fiscal 2025, which ended Sep 30, 2025, Regen Biopharma, Inc. used $383,591 of cash from operations, up 49.0% from the year before.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
FY 2020
Sep 30, 2020
|
FY 2019
Sep 30, 2019
|
FY 2018
Sep 30, 2018
|
FY 2017
Sep 30, 2017
|
FY 2016
Sep 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Stock-based compensation |
—
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Operating cash flow |
-0
-3.3%
|
-0
+49.0%
|
-1
-332.1%
|
-0
+71.3%
|
-1
+46.3%
|
-1
-6165.6%
|
0
+103.9%
|
-0
+69.5%
|
-2
+16.7%
|
-2
-13.3%
|
-2
|
| Investing | |||||||||||
| Investing cash flow |
—
|
—
|
—
|
—
|
0
-94.9%
|
0
|
0
-100.0%
|
0
+968.5%
|
-0
|
—
|
—
|
| Financing | |||||||||||
| Financing cash flow |
0
+19.7%
|
0
-28.3%
|
1
+159.0%
|
0
+359.2%
|
-0
-106.9%
|
1
+5243.8%
|
-0
-106.1%
|
0
-67.3%
|
1
-38.2%
|
2
+29.0%
|
2
+162.8%
|
| Change in cash | |||||||||||
| Net change in cash |
-0
|
0
+157.2%
|
-0
|
—
|
-1
|
—
|
—
|
—
|
—
|
—
|
—
|
| Ratios | |||||||||||
| Stock-based compensation to revenue |
—
|
—
|
5.52%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Cash conversion |
—
|
—
|
—
|
-0.15x
|
-0.25x
|
—
|
0.01x
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RGBP (OTC), RGBPP (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- La Mesa, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1589150
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.